Cargando…

TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer

Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Zhong, Runbo, Lou, Yuqing, Hu, Minjuan, Yang, Zhengyu, Wang, Yanan, Chen, Ya, Zou, Benkun, Zhang, Wei, Wang, Huimin, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485033/
https://www.ncbi.nlm.nih.gov/pubmed/34603310
http://dx.doi.org/10.3389/fimmu.2021.732125
_version_ 1784577452664684544
author Lu, Jun
Zhong, Runbo
Lou, Yuqing
Hu, Minjuan
Yang, Zhengyu
Wang, Yanan
Chen, Ya
Zou, Benkun
Zhang, Wei
Wang, Huimin
Han, Baohui
author_facet Lu, Jun
Zhong, Runbo
Lou, Yuqing
Hu, Minjuan
Yang, Zhengyu
Wang, Yanan
Chen, Ya
Zou, Benkun
Zhang, Wei
Wang, Huimin
Han, Baohui
author_sort Lu, Jun
collection PubMed
description Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss the potential stratification factors of NSCLC immunotherapy using immune checkpoint inhibitors (ICIs) by integrating genomic profiling and tumor lesion–type information. In this study, 344 patients with NSCLC, whose clinical and tissue (including metastatic and primary lesions) mutation information was available, were included. The potential gene mutation status for predicting the outcomes of immunotherapy was screened by comparing the difference in mutation frequency between responders and non-responders. Our results indicated that the potential predictors of immunotherapy were significantly different, especially between patients with TP53(+) (including metastatic and primary lesions) and TP53(−) (including metastatic and primary lesions). According to this classification, patients with NSCLC who suggested immunotherapy had a higher OS than those who did not (25 months vs. 7 months, P < 0.0001, hazard ratio = 0.39). Collectively, this study provides a new perspective for screening immunotherapy predictors in NSCLC, suggesting that the TP53 mutation status and source of biopsy tissue should be considered during the development of immunotherapy biomarkers.
format Online
Article
Text
id pubmed-8485033
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84850332021-10-02 TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer Lu, Jun Zhong, Runbo Lou, Yuqing Hu, Minjuan Yang, Zhengyu Wang, Yanan Chen, Ya Zou, Benkun Zhang, Wei Wang, Huimin Han, Baohui Front Immunol Immunology Immunotherapy, a chemotherapy-free process, has emerged as a promising therapeutic strategy to prolong the overall survival (OS) of patients with non-small-cell lung cancer (NSCLC). However, effective stratification factors for immunotherapy remain unclear. The purpose of this study was to discuss the potential stratification factors of NSCLC immunotherapy using immune checkpoint inhibitors (ICIs) by integrating genomic profiling and tumor lesion–type information. In this study, 344 patients with NSCLC, whose clinical and tissue (including metastatic and primary lesions) mutation information was available, were included. The potential gene mutation status for predicting the outcomes of immunotherapy was screened by comparing the difference in mutation frequency between responders and non-responders. Our results indicated that the potential predictors of immunotherapy were significantly different, especially between patients with TP53(+) (including metastatic and primary lesions) and TP53(−) (including metastatic and primary lesions). According to this classification, patients with NSCLC who suggested immunotherapy had a higher OS than those who did not (25 months vs. 7 months, P < 0.0001, hazard ratio = 0.39). Collectively, this study provides a new perspective for screening immunotherapy predictors in NSCLC, suggesting that the TP53 mutation status and source of biopsy tissue should be considered during the development of immunotherapy biomarkers. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8485033/ /pubmed/34603310 http://dx.doi.org/10.3389/fimmu.2021.732125 Text en Copyright © 2021 Lu, Zhong, Lou, Hu, Yang, Wang, Chen, Zou, Zhang, Wang and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lu, Jun
Zhong, Runbo
Lou, Yuqing
Hu, Minjuan
Yang, Zhengyu
Wang, Yanan
Chen, Ya
Zou, Benkun
Zhang, Wei
Wang, Huimin
Han, Baohui
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title_full TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title_fullStr TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title_full_unstemmed TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title_short TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
title_sort tp53 mutation status and biopsy lesion type determine the immunotherapeutic stratification in non-small-cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8485033/
https://www.ncbi.nlm.nih.gov/pubmed/34603310
http://dx.doi.org/10.3389/fimmu.2021.732125
work_keys_str_mv AT lujun tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT zhongrunbo tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT louyuqing tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT huminjuan tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT yangzhengyu tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT wangyanan tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT chenya tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT zoubenkun tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT zhangwei tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT wanghuimin tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer
AT hanbaohui tp53mutationstatusandbiopsylesiontypedeterminetheimmunotherapeuticstratificationinnonsmallcelllungcancer